MindBio Therapeutics (XCNQ:MBIO) Total Assets : C$0.28 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Total Assets?

MindBio Therapeutics's Total Assets for the quarter that ended in Mar. 2024 was C$0.28 Mil.

During the past 12 months, MindBio Therapeutics's average Total Assets Growth Rate was -91.90% per year.

Total Assets is connected with ROA %. MindBio Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 was 132.36%. Total Assets is also linked to Revenue through Asset Turnover. MindBio Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 was 1.87.

MindBio Therapeutics Total Assets Historical Data

The historical data trend for MindBio Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Total Assets Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Total Assets

0.45

1.45

0.60

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial					0.78	0.60	0.24	0.13	0.28

MindBio Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

MindBio Therapeutics's Total Assets for the fiscal year that ended in Jun. 2023 is calculated as

Total Assets	=	Total Equity (A: Jun. 2023 )	+	Total Liabilities (A: Jun. 2023 )
	=	-4.833	+	5.433
	=	0.60

MindBio Therapeutics's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	-4.995	+	5.272
	=	0.28

MindBio Therapeutics (XCNQ:MBIO) Total Assets Explanation

Total Assets is connected with ROA %.

MindBio Therapeutics's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	0.272	/	( (0.134	+	0.277)	/ 2 )
	=	0.272	/	0.2055
	=	132.36 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

MindBio Therapeutics's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0.384	/	( (0.134	+	0.277)	/ 2 )
=	0.384	/	0.2055
=	1.87

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

MindBio Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.